Bruker Corporation today announced the acquisition of Canopy Biosciences, LLC, a leader in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy. This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques. Bruker’s global reach, complementary technologies and applications knowledge will help build on Canopy’s success to date. Financial details of the transaction were not disclosed.
“We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker,” said Dr. Mark R. Munch, the Bruker NANO Group President. “Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”
Read more about this news here.
